| Literature DB >> 12360276 |
Robert Kerbel1, Judah Folkman.
Abstract
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?Entities:
Mesh：
Substances：
Year: 2002 PMID： 12360276 DOI： 10.1038/nrc905
Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716